Journal of Medicinal Chemistry
Article
(7) Brantley-Sieders, D. M. Clinical relevance of Ephs and ephrins in
cancer: lessons from breast, colorectal, and lung cancer profiling.
Semin. Cell. Dev. Biol. 2012, 23, 102−108.
(8) Beauchamp, A.; Debinski, W. Ephs and ephrins in cancer: ephrin-
A1 signalling. Semin. Cell. Dev. Biol. 2012, 23, 109−115.
(9) Merlos-Suarez, A.; Batlle, E. Eph-ephrin signalling in adult tissues
and cancer. Curr. Opin. Cell. Biol. 2008, 20, 194−200.
(10) Noren, N. K.; Pasquale, E. B. Paradoxes of the EphB4 receptor
in cancer. Cancer Res. 2007, 67, 3994−3997.
Agonist of EphA2 Receptor Tyrosine Kinase Inhibits Tumor Cell
Migration In Vitro and Prostate Cancer Metastasis in Vivo. PLoS One
2012, 7, e42120.
(26) Tognolini, M.; Giorgio, C.; Hassan Mohamed, I.; Barocelli, E.;
Calani, L.; Reynaud, E.; Dangles, O.; Borges, G.; Crozier, A.; Brighenti,
F.; Del Rio, D. Perturbation of the EphA2-EphrinA1 System in Human
Prostate Cancer Cells by Colonic (Poly)phenol Catabolites. J. Agric.
Food Chem. 2012, 60, 8877−8884.
(27) Noberini, R.; Koolpe, M.; Lamberto, I.; Pasquale, E. B.
Inhibition of Eph receptor−ephrin ligand interaction by tea
polyphenols. Pharmacol. Res. 2012, 66, 363−373.
(28) Mohamed, I. H.; Giorgio, C.; Bruni, R.; Flammini, L.; Barocelli,
E.; Rossi, D.; Domenichini, G.; Poli, F.; Tognolini, M. Polyphenol rich
botanicals used as food supplements interfere with EphA2−ephrinA1
system. Pharmacol. Res. 2011, 64, 464−470.
(29) Pfeffer, F. M.; Russell, R. A. Strategies and methods for the
attachment of amino acids and peptides to chiral [n]polynorbornane
templates. Org. Biomol. Chem. 2003, 1, 1845−1851.
(30) Chang, K. H.; Lee, L.; Chen, J.; Li, W. S. Lithocholic acid
analogues, new and potent alpha-2,3-sialyltransferase inhibitors. Chem.
Commun. 2006, 629−631.
(31) Wu, J.; Li, C.; Zhao, M.; Wang, W.; Wang, Y.; Peng, S. A class of
novel carboline intercalators: Their synthesis, in vitro anti-prolifer-
ation, in vivo anti-tumor action, and 3D QSAR analysis. Bioorg. Med.
Chem. 2010, 18, 6220−6229.
(32) Himanen, J. P. Ectodomain structures of Eph receptors. Semin.
Cell. Dev. Biol. 2012, 23, 35−42.
(11) Kuijper, S.; Turner, C. J.; Adams, R. H. Regulation of
angiogenesis by Eph-ephrin interactions. Trends Cardiovasc. Med.
2007, 17, 145−151.
(12) Martiny-Baron, G.; Holzer, P.; Billy, E.; Schnell, C.; Brueggen,
J.; Ferretti, M.; Schmiedeberg, N.; Wood, J. M.; Furet, P.; Imbach, P.
The small molecule specific EphB4 kinase inhibitor NVP-BHG712
inhibits VEGF driven angiogenesis. Angiogenesis 2010, 13, 259−267.
(13) Wang, S.; Placzek, W. J.; Stebbins, J. L.; Mitra, S.; Noberini, R.;
Koolpe, M.; Zhang, Z.; Dahl, R.; Pasquale, E. B.; Pellecchia, M. Novel
targeted system to deliver chemotherapeutic drugs to EphA2-
expressing cancer cells. J. Med. Chem. 2012, 55, 2427−2436.
(14) Tandon, M.; Vemula, S. V.; Mittal, S. K. Emerging strategies for
EphA2 receptor targeting for cancer therapeutics. Expert Opin. Ther.
Targets 2011, 15, 31−51.
(15) Lafleur, K.; Huang, D.; Zhou, T.; Caflisch, A.; Nevado, C.
Structure-based optimization of potent and selective inhibitors of the
tyrosine kinase erythropoietin producing human hepatocellular
carcinoma receptor B4 (EphB4). J. Med. Chem. 2009, 52, 6433−6446.
(16) Mamat, C.; Mosch, B.; Neuber, C.; Kockerling, M.; Bergmann,
R.; Pietzsch, J. Fluorine-18 Radiolabeling and Radiopharmacological
Characterization of a Benzodioxolylpyrimidine-Based Radiotracer
Targeting the Receptor Tyrosine Kinase EphB4. ChemMedChem
2012, 7, 1991−2003.
(17) van Linden, O. P.; Farenc, C.; Zoutman, W. H.; Hameetman, L.;
Wijtmans, M.; Leurs, R.; Tensen, C. P.; Siegal, G.; de Esch, I. J.
Fragment based lead discovery of small molecule inhibitors for the
EPHA4 receptor tyrosine kinase. Eur. J. Med. Chem. 2012, 47, 493−
500.
(18) Noberini, R.; Lamberto, I.; Pasquale, E. B. Targeting Eph
receptors with peptides and small molecules: progress and challenges.
Semin. Cell. Dev. Biol. 2012, 23, 51−7.
(19) Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit
in drug discovery at protein−protein interfaces. Nature 2007, 450,
1001−1009.
(20) Jehle, J.; Staudacher, I.; Wiedmann, F.; Schweizer, P. A.; Becker,
R.; Katus, H. A.; Thomas, D. Regulation of HL-1 cardiomyocyte
apoptosis by EphA2 receptor tyrosine kinase phosphorylation and
protection by lithocholic acid. Br. J. Pharmacol. 2012, 167, 1563−1572.
(21) Giorgio, C.; Hassan Mohamed, I.; Flammini, L.; Barocelli, E.;
Incerti, M.; Lodola, A.; Tognolini, M. Lithocholic acid is an Eph-
ephrin ligand interfering with Eph-kinase activation. PLoS One 2011, 6,
e18128.
(22) Tognolini, M.; Incerti, M.; Hassan-Mohamed, I.; Giorgio, C.;
Russo, S.; Bruni, R.; Lelli, B.; Bracci, L.; Noberini, R.; Pasquale, E. B.;
Barocelli, E.; Vicini, P.; Mor, M.; Lodola, A. Structure−activity
relationships and mechanism of action of Eph-ephrin antagonists:
interaction of cholanic acid with the EphA2 receptor. ChemMedChem
2012, 7, 1071−1083.
(33) Molecular Operating Environment (MOE), MOE 2008.10; CCG
Inc.: 1255 University Street, Montreal, Quebec, Canada, 2008.
(34) Himanen, J. P.; Goldgur, Y.; Miao, H.; Myshkin, E.; Guo, H.;
Buck, M.; Nguyen, M.; Rajashankar, K. R.; Wang, B.; Nikolov, D. B.
Ligand recognition by A-class Eph receptors: crystal structures of the
EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.
EMBO Rep. 2009, 10, 722−728.
(35) Glide 5.5; Schrodinger LLC: New York, 2009.
(36) Lyne, P. D.; Lamb, M. L.; Saeh, J. C. Accurate prediction of the
relative potencies of members of a series of kinase inhibitors using
molecular docking and MM-GBSA scoring. J. Med. Chem. 2006, 49,
4805−4808.
(37) Prime 3.0; Schrodinger LLC: New York, 2009.
(38) Rastelli, G.; Del Rio, A.; Degliesposti, G.; Sgobba, M. Fast and
accurate predictions of binding free energies using MM-PBSA and
MM-GBSA. J. Comput. Chem. 2010, 31, 797−810.
(39) Impact 5.8; Schrodinger LLC: New York, 2009.
(40) Guimaraes, C. R.; Cardozo, M. MM-GB/SA rescoring of
docking poses in structure-based lead optimization. J. Chem. Inf. Model.
2008, 48, 958−970.
(41) Lema Tome, C. M.; Palma, E.; Ferluga, S.; Lowther, W. T.;
Hantgan, R.; Wykosky, J.; Debinski, W. Structural and functional
characterization of monomeric EphrinA1 binding site to EphA2
receptor. J. Biol. Chem. 2012, 287, 14012−14022.
(42) Koolpe, M.; Dail, M.; Pasquale, E. B. An ephrin mimetic peptide
that selectively targets the EphA2 receptor. J. Biol. Chem. 2002, 277,
46974−94697.
(43) Noberini, R.; Rubio de la Torre, E.; Pasquale, E. B. Profiling Eph
receptor expression in cells and tissues: a targeted mass spectrometry
approach. Cell. Adhes. Migr. 2012, 6, 102−112.
(44) Miao, H.; Burnett, E.; Kinch, M.; Simon, E.; Wang, B. Activation
of EphA2 kinase suppresses integrin function and causes focal-
adhesion-kinase dephosphorylation. Nature Cell Biol. 2000, 2, 62−69.
(45) Baell, J. B.; Holloway, G. A. New substructure filters for removal
of pan assay interference compounds (PAINS) from screening libraries
and for their exclusion in bioassays. J. Med. Chem. 2010, 53, 2719−
2740.
(46) Pellicciari, R.; Gioiello, A.; Macchiarulo, A.; Thomas, C.;
Rosatelli, E.; Natalini, B.; Sardella, R.; Pruzanski, M.; Roda, A.;
Pastorini, E.; Schoonjans, K.; Auwerx, J. Discovery of 6alpha-ethyl-
23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective
(23) Noberini, R.; De, S. K.; Zhang, Z.; Wu, B.; Raveendra-Panickar,
D.; Chen, V.; Vazquez, J.; Qin, H.; Song, J.; Cosford, N. D.; Pellecchia,
M.; Pasquale, E. B. A disalicylic acid-furanyl derivative inhibits ephrin
binding to a subset of Eph receptors. Chem. Biol. Drug Des. 2011, 78,
667−678.
(24) Noberini, R.; Koolpe, M.; Peddibhotla, S.; Dahl, R.; Su, Y.;
Cosford, N. D.; Roth, G. P.; Pasquale, E. B. Small molecules can
selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J.
Biol. Chem. 2008, 283, 29461−29472.
(25) Petty, A.; Myshkin, E.; Qin, H.; Guo, H.; Miao, H.; Tochtrop,
G. P.; Hsieh, J. T.; Page, P.; Liu, L.; Lindner, D. J.; Acharya, C.;
Mackerell, A. D., Jr.; Ficker, E.; Song, J.; Wang, B. A Small Molecule
2946
dx.doi.org/10.1021/jm301890k | J. Med. Chem. 2013, 56, 2936−2947